RxDoctor Payments Data

Alan Reichman, MD

Family Medicine · Sugar Land, TXNPI 1245328376

Payments from drug & device makers

$2,395,742in general payments, 2019–2025

Across 2,534 payments — averaging $945.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$1.8M
  • Ipsen Innovation$227K
  • Novartis$152K
  • Pfizer$53K
  • GSK$33K
  • Sanofi US Services Inc.$29K
  • plus $63K from 39 others

What the payments were for

  • Food & beverage$5,44898%
  • Education$1142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,395,742 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$94,090
Medicare patients
265
Services billed
2,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol62$67,368
OzempicSemaglutide28$30,630
JardianceEmpagliflozin25$29,692
EliquisApixaban34$27,838
TradjentaLinagliptin25$21,083
JanumetSitagliptin Phos/Metformin Hcl17$14,723
JanuviaSitagliptin Phosphate17$14,151
Trijardy XrEmpaglifloz/Linaglip/Metformin13$9,048
Atorvastatin Calcium597$6,021
Rosuvastatin Calcium310$5,864
CreonLipase/Protease/Amylase13$5,721
SymbicortBudesonide/Formoterol Fumarate12$4,275
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide66$3,323
Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine70$3,264
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen81$3,263

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$17,811$71,64374 claims
Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr$229$59,82363 claims
Novo NordiskOzempic$888$30,63028 claims
MerckJanumet, Januvia$408$28,87434 claims
PfizerEliquis$53,427$27,83834 claims
AbbVieCreon, Synthroid$290$8,62850 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Sugar Land

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →